Locally Advanced Breast Cancer
Mostrando 1-12 de 22 artigos, teses e dissertações.
-
1. Hormone receptor-negative as a predictive factor for pathologic complete response to neoadjuvant therapy in breast cancer
RESUMO Objetivo Definir um fator preditivo para resposta patológica completa, comparar os resultados oncológicos associados com o grau de resposta patológica, após quimioterapia neoadjuvante, e analisar a resposta patológica completa como fator prognóstico para sobrevivência global e livre de progressão de doença. Métodos Estudo retrospectivo de
Einstein (São Paulo). Publicado em: 21/01/2019
-
2. Breast-conserving surgery in locally advanced breast cancer submitted to neoadjuvant chemotherapy. Safety and effectiveness based on ipsilateral breast tumor recurrence and long-term follow-up
OBJECTIVE: To evaluate ipsilateral breast tumor recurrence after breast-conserving surgery for locally advanced breast cancer. METHODS: A retrospective observational cohort study was performed in patients with locally advanced breast cancer submitted to breast-conserving surgery after neoadjuvant chemotherapy based on an adriamycin-cyclophosphamide-paclita
Clinics. Publicado em: 2017-03
-
3. Metronomic chemotherapy in the neoadjuvant setting: results of two parallel feasibility trials (TraQme and TAME) in patients with HER2+ and HER2− locally advanced breast cancer
Neoadjuvant chemotherapy has practical and theoretical advantages over adjuvant chemotherapy strategy in breast cancer (BC) management. Moreover, metronomic delivery has a more favorable toxicity profile. The present study examined the feasibility of neoadjuvant metronomic chemotherapy in two cohorts [HER2+ (TraQme) and HER2− (TAME)] of locally advanced BC
Braz J Med Biol Res. Publicado em: 06/03/2015
-
4. Expression of aldehyde dehydrogenase after neoadjuvant chemotherapy is associated with expression of hypoxia-inducible factors 1 and 2 alpha and predicts prognosis in locally advanced breast cancer
OBJECTIVE: To analyze the expression of hypoxia-inducible factors (hypoxia-inducible factor 1A and hypoxia-inducible factor 2A) and aldehyde dehydrogenase proteins in patients with locally advanced breast carcinoma who were subjected to neoadjuvant chemotherapy. METHODS: We included 90 patients with histologically confirmed stage II and III breast carcino
Clinics. Publicado em: 2013-05
-
5. Avaliação da expressão da proteína EZH2 na resposta do carcinoma de mama localmente avançado à quimioterapia neoadjuvante / EZH2 protein expression on the response to neoadjuvant chemotherapy in locally advanced breast cancer
INTRODUÇÃO: O tratamento de escolha do carcinoma de mama localmente avançado é a quimioterapia neoadjuvante, porém, em virtude da heterogeneidade tumoral, sabe-se que nem todos os tumores responderão a esse tratamento. Neste contexto, avaliamos a proteína EZH2 (Enhancer of Zest Homolog 2), uma histona-metiltransferase catalisadora da trimetilação da
IBICT - Instituto Brasileiro de Informação em Ciência e Tecnologia. Publicado em: 23/10/2012
-
6. Effect of neoadjuvant chemotherapy on low-density lipoprotein (LDL) receptor and LDL receptor-related protein 1 (LRP-1) receptor in locally advanced breast cancer
Low-density lipoprotein (LDL) receptors are overexpressed in most neoplastic cell lines and provide a mechanism for the internalization and concentration of drug-laden nanoemulsions that bind to these receptors. The aim of the present study was to determine whether the administration of standard chemotherapeutic schemes can alter the expression of LDL and LD
Brazilian Journal of Medical and Biological Research. Publicado em: 2012-06
-
7. Expression of Hypoxia-inducible factor 1-α and Vascular endothelial growth factor-C in locally advanced breast cancer patients
BACKGROUND: Locally advanced breast cancers are more prevalent in underdeveloped countries. Targeted therapy has been improved to identify hallmarks that are specific to these subtypes of tumors. OBJECTIVES: We aimed to prospectively assess the expression of Hypoxia inducible factor-1 α and vascular endothelial growth factor-C in locally advanced breast can
Clinics. Publicado em: 2011
-
8. Efeitos da quimioterapia neoadjuvante sobre os receptores de lipoproteínas no tecido tumoral em pacientes com carcinoma da mama localmente avançado / Effects of neoadjuvant chemotherapy on lipoprotein receptors in tumor tissues of patients with locally advanced breast cancer
Proliferative tumor cells present a high expression of LDL receptors due to accelerated mitosis rates which takes to increased need of lipids internalization for building new membranes. Upregulation of LDL receptors may be used as a gate to deliver anticancer drugs to tumor tissues using lipoproteins or artificial nanoemulsions as vehicle. This study investi
Publicado em: 2010
-
9. Produção de VEGF e HIF-1? em pacientes com carcinoma de mama localmente avançado submetidas à quimioterapia neoadjuvante. / Production of VEGF and HIF-1? in patients with locally advanced breast cancer primarily submitted to neoadjuvant chemotherapy.
To determine the predictive and prognostic value of vascular endothelial growth factor (VEGF) and Hypoxia-inducible factor-1 (HIF-1?) for relapse-free survival (RFS) and overall survival (OS) in locally advanced breast cancer (LABC) primarily submitted to neoadjuvant chemotherapy. MATERIALS AND METHODS: VEGF and HIF were quantitatively measured in plasma sam
IBICT - Instituto Brasileiro de Informação em Ciência e Tecnologia. Publicado em: 09/05/2008
-
10. Surgical adjuvant treatment of locally advanced breast cancer.
The reported incidence of local recurrence after mastectomy for locally advanced breast cancer (TNM Stage III and IV) is between 30% and 50%. The purpose of this study was to evaluate the effect of radiation therapy (XRT) followed by total mastectomy on the incidence of local recurrence in patients with locally advanced breast cancer. Fifty-three patients wh
-
11. Clinical practice guidelines for the care and treatment of breast cancer: 15. Treatment for women with stage III or locally advanced breast cancer
-
12. Treatment of locally advanced breast cancer